Healthcare provider profile · identity verified

Narinder Sandhu, MD

Family Practice · RANCHO CORDOVA, CA · NPI 1689605602

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	627	141
Amlodipine Besylate	Amlodipine Besylate	427	104
Metformin Hcl	Metformin Hcl	311	77
Lisinopril	Lisinopril	284	71
Losartan Potassium	Losartan Potassium	254	64
Ibuprofen	Ibuprofen	246	77
Gabapentin	Gabapentin	236	73
Levothyroxine Sodium	Levothyroxine Sodium	223	50
Omeprazole	Omeprazole	213	59
Tamsulosin Hcl	Tamsulosin Hcl	212	44
Alendronate Sodium	Alendronate Sodium	198	44
Metoprolol Succinate	Metoprolol Succinate	172	43
Furosemide	Furosemide	164	44
Simvastatin	Simvastatin	157	35
Metoprolol Tartrate	Metoprolol Tartrate	155	34
Omeprazole-Sodium Bicarbonate	Omeprazole/Sodium Bicarbonate	133	20
Jardiance	Empagliflozin	129	33
Albuterol Sulfate Hfa	Albuterol Sulfate	126	27
Clonidine Hcl	Clonidine Hcl	123	25
Carvedilol	Carvedilol	116	21
Rosuvastatin Calcium	Rosuvastatin Calcium	107	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	101	26
Donepezil Hcl	Donepezil Hcl	91	20
Glimepiride	Glimepiride	88	20
Baclofen	Baclofen	82	19
Clopidogrel	Clopidogrel Bisulfate	81	17
Januvia	Sitagliptin Phosphate	78	22
Janumet	Sitagliptin Phos/Metformin Hcl	77	20
Atenolol	Atenolol	76	16
Naproxen	Naproxen	72	24
Eliquis	Apixaban	69	14
Lovastatin	Lovastatin	68	13
Famotidine	Famotidine	59	24
Meclizine Hcl	Meclizine Hcl	59	28
Pantoprazole Sodium	Pantoprazole Sodium	57	17
Escitalopram Oxalate	Escitalopram Oxalate	54	17
Triamcinolone Acetonide	Triamcinolone Acetonide	53	27
Hydralazine Hcl	Hydralazine Hcl	52	17
Potassium Chloride	Potassium Chloride	51	suppressed
Trazodone Hcl	Trazodone Hcl	51	15
Allopurinol	Allopurinol	48	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	48	15
Nitroglycerin	Nitroglycerin	46	14
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	44	14
Diclofenac Sodium	Diclofenac Sodium	44	31
Valsartan	Valsartan	44	suppressed
Benazepril Hcl	Benazepril Hcl	43	suppressed
Dihydroergotamine Mesylate	Dihydroergotamine Mesylate	40	suppressed
Meloxicam	Meloxicam	40	15
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	36	suppressed
Glipizide	Glipizide	35	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	35	suppressed
Sertraline Hcl	Sertraline Hcl	34	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	33	13
Azithromycin	Azithromycin	32	26
Isosorbide Mononitrate Er	Isosorbide Mononitrate	32	suppressed
Fluticasone Propionate	Fluticasone Propionate	30	12
Ibu	Ibuprofen	28	suppressed
Vascepa	Icosapent Ethyl	28	suppressed
Finasteride	Finasteride	27	suppressed
Tradjenta	Linagliptin	27	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	26	suppressed
Paroxetine Hcl	Paroxetine Hcl	25	suppressed
Celecoxib	Celecoxib	24	suppressed
Clotrimazole	Clotrimazole	24	11
Janumet Xr	Sitagliptin Phos/Metformin Hcl	24	suppressed
Azelastine Hcl	Azelastine Hcl	22	suppressed
Glipizide Er	Glipizide	22	suppressed
Lactulose	Lactulose	22	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	21	suppressed
Methotrexate	Methotrexate Sodium	20	suppressed
Naftifine Hcl	Naftifine Hcl	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Farxiga	Dapagliflozin Propanediol	19	suppressed
Fenofibrate	Fenofibrate	18	suppressed
Ibuprofen-Famotidine	Ibuprofen/Famotidine	18	suppressed
Lidocaine	Lidocaine	18	suppressed
Ozempic	Semaglutide	18	suppressed
Prednisone	Prednisone	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Amoxicillin	Amoxicillin	17	15
Cyclosporine	Cyclosporine	17	suppressed
Lorazepam	Lorazepam	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	17	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Tavaborole	Tavaborole	17	suppressed
Icosapent Ethyl	Icosapent Ethyl	16	suppressed
Mirtazapine	Mirtazapine	16	suppressed
Nystatin	Nystatin	16	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	15	suppressed
Linzess	Linaclotide	15	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Pravastatin Sodium	Pravastatin Sodium	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Tramadol Hcl	Tramadol Hcl	14	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	13	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Humalog	Insulin Lispro	12	suppressed
Lumigan	Bimatoprost	12	suppressed
Benztropine Mesylate	Benztropine Mesylate	11	suppressed
Clonidine	Clonidine	11	suppressed
Dutasteride	Dutasteride	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Lurasidone Hcl	Lurasidone Hcl	11	suppressed
Methimazole	Methimazole	11	suppressed
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error